巨细胞动脉炎治疗失败预测因素分析
该研究为巨细胞动脉炎Actemra试验的事后分析,纳入250例患者,比较托珠单抗联合糖皮质激素与单用糖皮质激素的治疗失败预测因素。结果显示,单用泼尼松和女性是治疗失败的最强危险因素,托珠单抗联合组治疗失败风险显著低于安慰剂联合组(OR 0.2)。在托珠单抗联合组中,较低基线泼尼松剂量和较差的患者报告结局与治疗失败相关。
要点
- 单用泼尼松和女性是GCA治疗失败的最强危险因素。
- 托珠单抗联合泼尼松较单用泼尼松显著降低治疗失败风险(OR 0.2)。
- 托珠单抗组中较低基线泼尼松剂量和较差PROs与治疗失败相关。
核心结论
- GCA治疗失败的最强危险因素是单用泼尼松和女性。
- 较低起始泼尼松剂量和受损的患者报告结局与托珠单抗应答失败相关。
研究设计与样本
- 巨细胞动脉炎Actemra试验的事后分析,纳入250例患者,按意向治疗人群分析。
- 患者接受每周托珠单抗联合26周泼尼松减量(n=100)、每两周托珠单抗联合26周泼尼松减量(n=49)、安慰剂联合26周泼尼松减量(n=50)或安慰剂联合52周泼尼松减量(n=51)。
- 治疗失败定义为第12周时未能达到缓解或第12周至第52周之间复发。
主要发现
- 149例接受托珠单抗联合泼尼松(TCZ/PDN),101例接受安慰剂联合泼尼松(PBO+PDN)。
- 调整混杂因素后,TCZ/PDN组治疗失败风险显著低于PBO/PDN组(OR 0.2;95%CI 0.1至0.3;p<0.0001)。
- PBO/PDN组中女性治疗失败风险显著高于男性(OR 5.2;95%CI 1.6至17.2;p=0.007),TCZ/PDN组无此差异。
- TCZ/PDN组治疗失败的预测因素包括较低基线泼尼松剂量和较差基线患者报告结局。
关键数值与推荐
- 缓解定义为无GCA体征/症状且无红细胞沉降率升高,持续至第52周。
- 治疗失败定义为第12周时未能达到缓解或第12周至第52周之间复发。
临床怎么用
- 对于GCA患者,尤其是女性,单用泼尼松治疗失败风险较高,应考虑联合托珠单抗。
- 使用托珠单抗时,较低起始泼尼松剂量和较差患者报告结局可能提示应答不佳,需密切监测。
局限性
- 本研究为事后分析,结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Identify predictors of treatment failure in patients with giant cell arteritis (GCA) receiving tocilizumab in combination with glucocorticoids and in patients with GCA receiving only glucocorticoids. METHODS: Posthoc analysis of the Giant-Cell Arteritis Actemra trial including 250 patients who received tocilizumab every week plus a 26-week prednisone taper (n=100), tocilizumab every-other-week plus a 26-week prednisone taper (n=49) or placebo plus a 26-week (n=50) or 52-week (n=51) prednisone taper in the intention-to-treat population. Responders for this analysis were patients who maintained remission (no GCA signs/symptoms and no erythrocyte sedimentation rate elevation) through week 52. Treatment failure was defined as inability to achieve remission by week 12 or relapse between weeks 12 and 52. Predictors investigated in univariate and multivariable analyses included patient characteristics, disease-related and treatment-related factors and patient-reported outcomes (PROs). RESULTS: 149 patients received tocilizumab plus prednisone (TCZ/PDN) and 101 received placebo plus prednisone (PBO+PDN). After adjustment for confounders, treatment failure was significantly less likely in the TCZ/PDN group than the PBO/PDN group (OR, 0.2; 95% CI, 0.1 to 0.3; p<0.0001). Risk for treatment failure was significantly higher in women than men in the PBO/PDN group (OR, 5.2; 95% CI, 1.6 to 17.2; p=0.007) but not in the TCZ/PDN group. Predictors of treatment failure in the TCZ/PDN group included lower baseline prednisone doses and worse PROs at baseline. CONCLUSION: The strongest risk factors for treatment failure in GCA are treatment with prednisone alone and female sex. Lower starting prednisone doses and impaired PROs are associated with failure to respond to tocilizumab. TRIAL REGISTRATION NUMBER: NCT01791153.
引用
- Unizony SH, Bao M, Han J, et al. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021. PMID: 34049857. doi:10.1136/annrheumdis-2021-220347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。